Walts Alan Edmund 4

What Happened
Alan Edmund Walts, a director of Eloxx Pharmaceuticals (ELOX), received a grant of derivative securities on 2026-06-08 covering 8,590 shares. The grant shows $0.00 paid at acquisition (i.e., no cash exchanged at grant). This was an award (not an open-market purchase or sale) and represents a compensation-related option grant rather than an immediate stock purchase.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-10 (timely filing).
• Transaction type/code: Award/Grant (A) of a derivative security; reported price at grant: $0.00; reported total value: $0.
• Vesting: The option vests in 24 substantially equal monthly installments and will be fully vested and exercisable on the second anniversary of the grant date, subject to continuous service (per filing footnote).
• Shares owned after transaction: Not specified in the filing.
• This is a compensation grant (derivative security), not an exercised option, sale, or open-market purchase.

Context
Option grants are common executive/director compensation and do not by themselves indicate a buy or sell signal. The award will convert to exercisable options as they vest; there was no immediate cash transaction or sale reported at grant.